ECU Libraries Catalog

Public health effectiveness of FDA 510(k) clearance process : measuring postmarket performance and other select topics : workshop report / Theresa Wizemann, editor ; Committee on the Public Health Effectiveness of the FDA 510(k) Clearance Process, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies.

Other author/creatorWizemann, Theresa M.
Other author/creatorInstitute of Medicine (U.S.). Committee on the Public Health Effectiveness of the FDA 510(k) Clearance Process.
Format Electronic and Book
Publication InfoWashington, D.C. : National Academies Press,
Descriptionxiv, 118 p. : ill. (some col.) ; 23 cm.
Supplemental Content Full text available from Ebook Central - Academic Complete
Subject(s)
Running title FDA 510(k) clearance process
Contents Introduction -- Food and Drug Administration postmarking surveillance activities and recall studies of medical devices.
Abstract "The Food and Drug Administration (FDA) is responsible for ensuring that medical devices are safe and effective before they go on the market. Section 510(k) of the Federal Food, Drug, and Cosmetic Act requires a manufacturer of medical devices to notify FDA of its intent to market a medical device at least 90 days in advance. That window of time allows FDA to evaluate whether the device is substantially equivalent to a product already legally on the market (called a predicate), in which case the device does not need to go through the premarket approval (PMA) process. As part of its assessment of the FDA's premarket clearance process for medical devices, the Institute of Medicine (IOM) held a workshop on July 28, 2010 to discuss how medical devices are monitored for safety after they are available to consumers. Its primary focus was on monitoring the safety of marketed medical devices, including FDA's postmarket surveillance activities, analysis of safety concerns that resulted in medical device recalls, and non-FDA sources of adverse-event information. Public Health Effectiveness of the FDA 501(K) Clearance Process summarizes the views of the workshop participants."--Publisher's description.
Bibliography noteIncludes bibliographical references.
Access restrictionAvailable only to authorized users.
Other formsAlso available in Open Book format via the National Academies Press home page.
Technical detailsMode of access: World Wide Web
Genre/formElectronic books.
LCCN 2011284660
ISBN0309162068
ISBN9780309162067

Available Items

Library Location Call Number Status Item Actions
Electronic Resources Access Content Online ✔ Available